Afsaneh Vazin
Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Mojtaba Mojtahedzadeh
Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Ebrahim Salehifar
Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Noushin Rastkari
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Siavash Khalaj
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Ali Rezaie
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Abdollahi
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
ABSTRACT
The acute respiratory distress syndrome (ARDS) is a common clinical disorder characterized by injury to the alveolar epithelial and endothelial barriers of the lung, acute inflammation and pro rich pulmonary edema leading to acute respiratory failure. Knowledge of the pathophysiology and management of ARDS has been improved immensely since its original description. But pharmacotherapies have not been hopeful in treatment of ARDS in clinical trials. Mortality from ARDS has decreased in certain centers over the last 10 years due to advances in supporting critically ill patients. This trend may open the window of opportunity for pharmacological manipulation of ARDS. This study reviews conventional and new treatment challenges like use of nitric oxide nebulizer, prostacycline, surfactants, anti-inflammatory agents, antioxidants, phosphodiesterase inhibitors, immunonutrients, prostaglandin E1, anti-interleukins and inhibitors of thromboxanes and leucotriens
PDF References
How to cite this article
Afsaneh Vazin, Mojtaba Mojtahedzadeh, Ebrahim Salehifar, Noushin Rastkari, Siavash Khalaj, Ali Rezaie and Mohammad Abdollahi, 2005. Future
Drugs for Treatment of Acute Respiratory Distress Syndrome. International Journal of Pharmacology, 1: 9-16.
DOI: 10.3923/ijp.2005.9.16
URL: https://scialert.net/abstract/?doi=ijp.2005.9.16
DOI: 10.3923/ijp.2005.9.16
URL: https://scialert.net/abstract/?doi=ijp.2005.9.16
REFERENCES
- Bernard, G.R., A. Artigas, K.L. Brigham, J. Carlet, K. Falke and L. Hudson et al., 1994. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med., 120: 225-232.
CrossRefDirect Link - Hudson, L.D. and K.P. Steinberg, 1999. Epidemiology of acute lung injury and ARDS. Chest, 116: 74S-82S.
CrossRefDirect Link - Ware, L.B. and M.A. Matthay, 2000. The acute respiratory distress syndrome. N. Engl. J. Med., 342: 1334-1342.
Direct Link - Cranshaw, J., M.J.D. Griffiths and T.W. Evans, 2002. The pulmonary physician in critical care. 9: Non-ventilatory strategies in ARDS. Thorax, 57: 823-829.
CrossRefPubMedDirect Link - Feratacci, M.D., C.G. Frostell, T.Y. Chen, J.C. Wain Jr, D.R. Robinson and W.M. Zapol, 1991. Inhaled nitric oxide: A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology, 75: 990-999.
PubMedDirect Link - Shah, N.S., D.K. Nakayama and T.D. Jacobe, 1994. Efficacy of inhaled nitric oxide in a porcine model of adult respiratory distress syndrome. Arch. Surg., 129: 158-164.
Direct Link - Dellinger, R.P., J.L. Zimmerman, R.W. Taylor, R.C. Straube and D.L. Hauser et al., 1998. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial, Inhaled nitric oxide in ARDS study group. Crit. Care Med., 26: 15-23.
PubMedDirect Link - Gelach, H., R. Rossaint, D. Pappert and K.J. Falke, 1993. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur. J. Clin. Invest., 23: 499-502.
PubMedDirect Link - Bone, R., G. Slotman, R. Maunder, H. Silverman, T.M. Hyers, M.D. Kerstein and J.J. Ursprung, 1989. Randomized double-blind multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome, prostaglandin E1 study group. Chest, 96: 114-119.
CrossRefDirect Link - Meyer, J., G. Theilmeier, H. Van Aken, H.G. Bone and H. Busse et al., 1998. Inhaled prostacyclin E1 for treatment of acute lunge injury in severe multiple organ failure. Anesth Analg., 86: 735-738.
Direct Link - Ahuja, A., N. Oh, W. Chao, R.G. Spragg and R.M. Smith, 1996. Inhibitionof the human neutrophil respiratory burst by native and synthetic surfactant. Am. J. Respiratory Cell. Mol. Biol., 14: 496-503.
PubMedDirect Link - Chao, W., R.G. Spragg and R.M. Smith, 1995. Inhibitory effects of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. J. Clin. Invest., 96: 2654-2660.
CrossRefDirect Link - Suwabe, A., K. Otake, N. Yakuwa, S. Hiroki and I. Miyuki et al., 1998. Artificial surfactant (Surfactant TA) modulates adherence and superoxide production of neutrophils. Am. J. Respiratory Crit. Care Med., 158: 1890-1899.
Direct Link - Lewis, J.F. and A.H. Jobe, 1993. Surfactant and the adult respiratory distress syndrome. Am. Rev. Respiratory Dis., 147: 218-223.
Direct Link - Bellingan, G.J., 2002. The pulmonary physician in critical care. 6: The pathogenesis of ALI/ARDS. Thorax, 57: 540-546.
CrossRefPubMedDirect Link - Richman, P.S., R.G. Spragg, B. Robertson, T.A. Merritt and T. Curstedt, 1989. The adult respiratory distress syndrome: First trials with surfactant replacement. Eur. Respiratory J. Suppl., 3: 109s-111s.
Direct Link - Lachman, B., 1989. Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome. Eur. Respiratory J. Suppl., 3: 98s-103s.
PubMedDirect Link - Weg, J.G., R.A. Balk, R.S. Tharratt, S.G. Jenkinson and J.B. Shah et al., 1994. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced in adult respiratory distress syndrome. J. Am. Med. Assoc., 272: 1433-1438.
Direct Link - Gregory, T.J., K.P. Steinberg, R. Spragg, J.E. Gadek and T.M. Hyers et al., 1997. Bovine surfactant therapy for patient with acute respiratory distress syndrome. Am. J. Respiratory Crit. Care Med., 155: 1309-1315.
Direct Link - Mcintyre, R.C., E.J. Pulido, D.D. Bensard, B.D. Shames and E. Abraham, 2000. Thirty years of clinical trials in acute respiratory distress syndrome. Crit. Care Med., 28: 3314-3331.
PubMedDirect Link - Sprung, C.L., P.V. Caralis, E.H. Marcial, M. Pierce and M.A. Gelbard et al., 1984. The effects of high dose corticosteroids in patients with septic shock: A prospective, controlled study. New Engl. J. Med., 311: 1137-1143.
PubMedDirect Link - Bernars, G.R., J.M. Luce, C.L. Sprung, J.E. Rinaldo and R.M. Tate et al., 1987. High dose corticosteroids in patients with adult respiratory distress syndrome. New Engl. J. Med., 317: 1565-1570.
Direct Link - Bernard, G.R., J.L. Vincent and P.F. Laterre, 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 344: 699-709.
Direct Link - Matthay, M.A., 2001. Severe sepsis: A new treatment with both anticoagulant and anti-inflammatory properties. New Engl. J. Med., 344: 759-762.
Direct Link - Weiss, Y.G., A.Maloyan, J. Tazelaar, R. Nichelle and D.S. Clifford, 2002. Adenovirus transfer of HSP-70 into pulmonary epithelium ameliorates experimental acute respiratory distress syndrome. J. Clin. Invest., 110: 801-806.
CrossRefPubMedDirect Link - Slutsky, A.S., 2002. Hot new therapy for sepsis and the acute respiratory distress syndrome. J. Clin. Invest., 110: 737-739.
CrossRefPubMedDirect Link - Bone, R.C., C.J. Fisher, T.P. Clemmer, G.J. Slotman and C.A. Metz, 1987. Early methylprednisolone treatment for septic syndrome and adult respiratory distress syndrome. Chest, 92: 1032-1036.
CrossRefDirect Link - Kaminski, N., J.D. Allard, J.F. Pittet, Z. Fengrong and G.J.D. Mark et al., 2000. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc. Nalt. Acad. Sci. USA., 97: 1778-1783.
Direct Link - Bernard, G.R., W.D. Lucht and M.E. Niedermeyer, J.R. Snapper, M.L. Ogletree and K.L. Brigham, 1984. Effect of N-acetylcycteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J. Clin. Invest., 73: 1772-1784.
PubMedDirect Link - Blackwell, T.S., T.R. Blackwell, E.P. Holdon, B.W. Christman and J.W. Christman, 1996. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J. Immunol., 157: 1630-1637.
PubMedDirect Link - Leff, J.A., C.P. Wilk, B.M. Hybertson, P.F. Shanley, C.J. Beehler and J.E. Repine, 1993. Postinsult treatment with N-acetyl-L-cysteine decreases IL-1-induced neutrophil influx and lung leak in rats. Am. J. Phsyiol., 265: L501-L506.
Direct Link - Bernard, G.R., 1991. N-acetylcycteine in experimental and clinical acute lung injury. Am. J. Med., 91: 54S-59S.
PubMedDirect Link - Ortolani, O., A. Cante, A.R. de Gaudio, M. Masoni and G. Novelli, 2000. L Protective effects of N-acetylcycteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock, 13: 14-18.
Direct Link - Domenighetti, G., P.M. Suter and M.D. Schaller, R. Ritz and C. Perret, 1997. Treatment with N-acetylcycteine during acute respiratory distress syndrome, a randomized double blind, placebo-controlled clinical study. J. Crit. Care, 12: 177-182.
PubMedDirect Link - Welsh, C.H., D. Lien, G.S. Worthen and J.V. Weil, 1998. Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am. Rev. Respiratory Dis., 138: 1106-1114.
Direct Link - Kudoh, I., M. Ohtake, H. Nishizawa, K. Kurahashi and S. Hattori et al., 1995. The effect of Pentoxifylline on acid-induced alveolar epithelial injury. Anesthesiology, 82: 531-541.
Direct Link - Brusten, S.L., D.A. Federighi, P. Parsons, W.E. Harris and E. Abraham et al., 1996. An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. Crit. Care Med., 24: 1129-1136.
PubMedDirect Link - Anonymous, 2002. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit. Care Med., 30: 1-6.
PubMed - Chang, D.W., L. Desanti and R.H. Demling, 1998. Anticatabolic and anabolic strategies in critical illness: A review of current treatment modalities. Shock, 10: 155-160.
PubMedDirect Link - Gadek, J.E., S.J. DeMichele, M.D. Karlstad, E.R. Pacht and M. Donahoe et al., 1999. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in patients with acute respiratory distress syndrome. Enteral nutrition in ARDS study group. Intensive Care Med., 27: 1409-1420.
PubMedDirect Link - Beale, R.J., D.J. Bryg and D.J. Bihare, 1999. Immunonutrition in the critically ill: A systemic review of clinical outcome. Crit. Care Med., 27: 2799-2805.
PubMedDirect Link - Silverman, H.J., G. Slotman, R.C. Bone, R. Maunder, T.M. Hyers, M.D. Kerstein and J.J. Ursprung, 1990. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from prostaglandin E1 multicenter trial. The prostaglandin E1 study group. Chest, 98: 405-410.
CrossRefDirect Link - Holcroft, J.W., M.J. Vassar and C.J. Weber, 1986. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome: A prospective trial. Ann. Surg., 203: 371-378.
Direct Link - Abraham, E., R. Bauchman and E. Fletcher, S. Heard and J. Lamberti et al., 1999. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: A placebo-controlled, randomized, double blind, multicenter clinical trial. TLC C-53 ARDS study group. Crit. Care Med., 27: 1478-1481.
PubMedDirect Link - Donnelly, S.C., R.M. Strieter and S.L. Kunkel, A. Walz and C.R. Robertson et al., 1993. Interlukin-8 and development of adult respiratory disress syndrome in at-risk patient groups. Lancet, 341: 643-647.
PubMedDirect Link - Hardaway, R.M., H. Harke, A.H. Tyroch, C.H. Williams, Y. Vazquez and G.F. Krause, 2001. Treatment of severe acute respiratory distress syndrome: A final report on a phase I study. Am. Surg., 67: 377-382.
Direct Link - Petrak, R.A., R.A. Balke and R.C. Bone, 1989. Prostaglandis, cyclo-oxygenase inhibitors and thromboxan synthetase inhibitors in the pathogeneses of multiple systems organ failure. Crit. Care Clin., 5: 303-314.
PubMedDirect Link - Pittet, J.F., R.C. Mackersie, T.R. Martin and M.A. Matthay, 1997. Biological markers of acute lung injury: Prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med., 155: 1187-1205.
PubMedDirect Link - Yu, M. and G. Tomasa, 1993. A double blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med., 21: 1635-1642.
PubMedDirect Link